Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

2.99
-0.2400-7.43%
Post-market: 2.990.00000.00%16:20 EDT
Volume:1.55M
Turnover:4.61M
Market Cap:138.44M
PE:-1.00
High:3.23
Open:3.21
Low:2.87
Close:3.23
Loading ...

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
Yesterday

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire
·
27 Mar

4D Molecular Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

BRIEF-4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy

Reuters
·
10 Mar

4Dmt Announces First Patients Enrolled in 4Front-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet Amd

THOMSON REUTERS
·
10 Mar

4D Molecular Therapeutics Inc - 4Front-2 Trial Expected to Initiate in Q3 2025

THOMSON REUTERS
·
10 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

4D Molecular price target lowered to $35 from $39 at RBC Capital

TipRanks
·
04 Mar

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

MT Newswires Live
·
04 Mar

4D Molecular price target lowered to $28 from $30 at Chardan

TIPRANKS
·
04 Mar

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
04 Mar

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Mar

Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating

TIPRANKS
·
03 Mar

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alcon (ALC) and Cooper Co (COO)

TIPRANKS
·
03 Mar